
LEQEMBI® (Lecanemab) Launches in China for Alzheimer’s Disease Treatment
Biogen, headquartered in Cambridge, Massachusetts, and led by CEO Christopher A. Viehbacher, announced today the launch of “LEQEMBI®” (known as “乐意保®” in China), a humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal…













